Diagnostic Delay Turned a Routine Reflux Visit Into a Gastric Cancer Workup
Pepe was 45 years old, living in Cali, Colombia, and working as a self-employed hauler of goods with a wheelbarrow when he first sought care in 2010 for several months of abdominal heaviness and non-exertional substernal burning. The first clinical interpretation was gastro-oesophageal reflux disease, and omeprazole was prescribed. For a patient with upper gastrointestinal symptoms, that initial decision is common enough to seem unremarkable. In this case, though, the symptom pattern continued to evolve, and the interval between first presentation and definitive visualization of the stomach became the central issue.
Ten weeks later, the symptoms had slowly worsened. A second visit prompted gastroscopy, but the procedure did not occur until 2 months after it was ordered. Endoscopy then revealed an ulcerated mass. In a disease such as gastric cancer, every delay before tissue-level assessment can matter because early lesions often mimic benign dyspepsia, reflux, or epigastric discomfort. The stomach and distal esophagus are particularly unforgiving sites for diagnostic hesitation: malignant lesions can produce nonspecific symptoms for months, while acid suppression may temporarily soften the very complaints that would otherwise trigger a faster workup.
This case captures a familiar failure mode in digestive oncology. A working diagnosis based on symptoms alone can be reasonable at the bedside, but it becomes fragile when the symptom course does not behave like uncomplicated reflux. Persistent heaviness, refractory burning, and progression over time should shift attention away from empiric therapy and toward structural disease. The ulcerated mass found on gastroscopy is the kind of result that justifies that shift. By the time an endoscope reaches the lesion, the question is no longer whether the symptoms are functional or inflammatory; the question is how much time elapsed before anatomy was finally inspected.
Empiric Acid Suppression Can Mask a More Serious Process
Omeprazole was a clinically understandable first choice. Proton pump inhibitors are widely used for reflux-like complaints, and many patients improve quickly. Yet symptom response is not the same as diagnostic certainty. Upper abdominal discomfort, postprandial fullness, and chest or substernal burning can arise from acid-mediated irritation, peptic disease, motility disorders, or cancer. When symptoms persist or worsen despite treatment, the differential diagnosis has to expand rather than contract.
The sequence in Pepe’s case illustrates how diagnostic delay can emerge even when no single clinician appears to make a glaring error. A provisional reflux diagnosis, a return visit 10 weeks later, a gastroscopy order, and then a further 2-month wait for the procedure each seem defensible in isolation. Together, they create a long corridor between first presentation and diagnosis. In gastric malignancy, that corridor is clinically important because tumor growth, luminal narrowing, mucosal ulceration, and occult bleeding can all advance while symptoms remain frustratingly ordinary.
Heaviness is not a trivial word in gastrointestinal medicine. Patients use it when they feel pressure, fullness, slowness, or an internal burden they cannot precisely localize. Combined with burning symptoms, it often points clinicians toward dyspepsia or reflux. Yet gastric cancer often begins as exactly that kind of vague discomfort, which is why the tempo of symptoms matters as much as their character. A stable complaint over years suggests one process; a complaint that worsens over weeks and months deserves a different level of urgency.
Endoscopy as the Turning Point in Upper Gastrointestinal Symptoms
Gastroscopy is not just another test in this setting. It is the decisive bridge from symptom management to lesion identification. Once the endoscope exposed an ulcerated mass, the clinical frame changed from empiric treatment to oncologic evaluation. The narrative becomes even more compelling because the lesion was not discovered at the first medical contact, but after a period of symptomatic progression and procedural delay.
The bedside implication is straightforward even if the broader systems lesson is uncomfortable: persistent upper gastrointestinal symptoms in adults, especially when they worsen despite therapy, should trigger timely endoscopic evaluation. The stomach is not a forgiving organ for long observation when malignancy is on the table. A lesion that can ulcerate is already announcing biological aggression, and the delay before visualization may separate treatable disease from more advanced disease.
Pepe’s occupation also adds a social dimension without requiring speculation about his exact income or insurance status. He worked as a self-employed hauler of goods with a wheelbarrow, a job that suggests physically demanding labor and little room for prolonged disruption. In that setting, repeated clinic visits, symptom persistence, and waiting for a procedure can all collide with practical barriers to care. The title of the piece, “Temporal rationing,” points directly at that reality: time itself becomes a limited resource, and diagnostic access is rationed across appointments, referrals, and procedure slots.
Gastric Cancer Often Hides Behind Common Symptoms
The biology of gastric cancer helps explain why this kind of story repeats in clinical practice. Early lesions may not announce themselves with dramatic bleeding or obstruction. They can instead produce symptoms that overlap with benign upper GI disease, which delays recognition until the lesion becomes visible or structurally destructive. Ulceration, once present, implies loss of mucosal integrity and a tumor environment capable of sustained local injury.
That overlap creates a clinical trap. If the working diagnosis is reflux, then acid suppression is sensible. If the symptoms are actually malignant, the same treatment may buy comfort while buying time for the tumor. This is why worsening symptoms deserve renewed diagnostic attention rather than simply more of the same medication. The failure is not only one of suspicion; it is also one of timing, because a disease hidden in ordinary symptoms can exploit a slow system.
Pepe’s case does not provide staging, histology, treatment, or outcome beyond the endoscopic finding of an ulcerated mass. Those missing details matter, and their absence is part of the clinical uncertainty. Even so, the sequence from first presentation to gastroscopy is enough to show how a relatively ordinary symptom complex can travel through a delayed pathway before a cancer diagnosis comes into view. The ulcerated mass was not incidental; it was the endpoint of a prolonged diagnostic interval that began with what looked like reflux.
A Delay Measured in Symptoms, Referrals, and Waiting
The most sobering feature of this case is how ordinary each step appears until the whole chain is assembled. Initial symptoms were nonspecific. Empiric therapy was started. The patient returned when he worsened. Endoscopy was ordered. The scope was delayed. Only then was the lesion seen.
For clinicians, the lesson is to let symptom evolution overrule diagnostic comfort. For systems of care, the case exposes how procedural waiting can become a clinical variable of its own. In upper gastrointestinal oncology, that variable is not abstract. It determines when a mass is found, when biopsy can begin, and how much disease has time to declare itself before anyone looks directly at the mucosa.